The market sell-off is creating opportunities for long-term investors to buy leading stocks at lower prices.
Four drugs made a huge impact on patient survival in 2015 according to clinical trials, and one of them can be bought over the counter.
AstraZeneca is taking dead aim at AbbVie's heir apparent to Humira. Should investors be worried?
A pending approval of a new hepatitis C cocktail could shake up the market in 2016, but don't count Gilead Sciences out yet.
A new competitive threat could imperil Imbruvica's fast growth as a treatment for a life-threatening cancer.
The FDA's approval of new cardiovascular and oncology disease drugs are among the most notable of the year.
New drug approvals promise to spell relief for countless patients -- find out which ones stood out over the past year.
The FDA's approval of Empliciti could reshape second-line multiple myeloma treatment.
The Pfizer-Allergan deal may not be the last tax inversion deal we witness. These three companies could also become the target of a U.S.-based buyer.
A proposed ban on direct-to-consumer prescription drug advertising could spell trouble for the industry's biggest ad spender.